<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04705389</url>
  </required_header>
  <id_info>
    <org_study_id>DR200079</org_study_id>
    <nct_id>NCT04705389</nct_id>
  </id_info>
  <brief_title>SerUM Markers in MERkel Cell Carcinoma Patients: a Longitudinal moniTorIng Study for optiMization of European Guidelines</brief_title>
  <acronym>SUMMERTIME</acronym>
  <official_title>SerUM Markers in MERkel Cell Carcinoma Patients: a Longitudinal moniTorIng Study for optiMization of European Guidelines</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Tours</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>European Academy of Dermatology and Venerology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Tours</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Merkel cell carcinoma (MCC) is a rare aggressive skin carcinoma. Approximately 80% of MCC are&#xD;
      related to the Merkel Cell Polyomavirus (MCPyV). Although rates of relapse are high, the&#xD;
      follow-up strategy lacks consensus. Patients are usually assessed clinically every 3 to 6&#xD;
      months for the first 2-3 years, and every 6 to 12 months thereafter. In the European&#xD;
      guidelines, patients with early stages are monitored with clinical examination and&#xD;
      ultrasonography of lymph nodes, while whole-body imaging is optional in patients with stage&#xD;
      III disease, on a yearly basis for 5 years. Such strategy may prevent the diagnosis of&#xD;
      infra-clinical recurrences, whereas patients could still be treated with surgery or radiation&#xD;
      therapy. Until 2017, patients with advanced disease were treated with chemotherapies, with no&#xD;
      long-term benefit. Immunotherapies with PD-1/PD-L1 inhibitors currently allow durable&#xD;
      responses in 50% of such patients. This major change in the management of MCC patients argues&#xD;
      for a follow-up strategy that would allow early diagnosis of infra-clinical metastases, when&#xD;
      tumoral burden is still low. Given that all patients cannot be monitored by systematic&#xD;
      regular imaging, additional non-invasive tools are needed. Blood-based biomarkers as a&#xD;
      surrogate of tumor burden are advantageous as they can be repeated over time, providing&#xD;
      guidance on when imaging is necessary. The study aims to assess two blood biomarkers, MCPyV&#xD;
      T-Ag antibodies and cell-free miR-375, in a prospective fashion from baseline diagnosis, in a&#xD;
      cohort of 150 European MCC patients&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2021</start_date>
  <completion_date type="Anticipated">September 2023</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess the diagnostic performances of two blood biomarkers (T-antigen antibodies and miR375) in detecting disease recurrence during follow up of patients with Merkel Cell Carcinoma</measure>
    <time_frame>12 months</time_frame>
    <description>Diagnostic performances (specificity, sensitivity, predictive values) of each biomarker will be assessed at the end of follow up, in relation with patients' outcomes (remission and recurrence).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess if these two blood biomarkers (T-antigen antibodies and miR375) assessed at baseline are associated with prognosis and response to treatments.</measure>
    <time_frame>12 months</time_frame>
    <description>Cox regression analysis will be performed to evaluate the clinical and biological factors associated with recurrence, death of disease, response to treatments.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Merkel Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>Case group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Intervention only includes additional blood sampling at baseline and during follow up (5 samplings).</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Samples</intervention_name>
    <description>blood samples</description>
    <arm_group_label>Case group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with a &quot; de novo &quot; diagnosis of MCC, confirmed on histological criteria&#xD;
             (neuroendocrine morphology, CK20 staining and/or neuroendocrine and/or SATB2 staining,&#xD;
             exclusion of differential diagnosis)&#xD;
&#xD;
          -  â‰¥ 18 years of age&#xD;
&#xD;
          -  Written informed consent obtained from the participant&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients following any measures of legal presentation&#xD;
&#xD;
          -  Pregnancy or breastfeeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mahtab SAMIMI, MD-PhD</last_name>
    <role>Study Director</role>
    <affiliation>University Hospital, Tours</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mahtab SAMIMI, MD-PhD</last_name>
    <phone>02.47.47.46.25</phone>
    <phone_ext>+33</phone_ext>
    <email>mahtab.samimi@univ-tours.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Dermatology, Medical University of Vienna</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
    <contact>
      <last_name>Robert Loewe, MD</last_name>
      <email>robert.loewe@meduniwien.ac.at</email>
    </contact>
    <investigator>
      <last_name>Robert Loewe</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital of Helsinki, Finland</name>
      <address>
        <city>Helsinki</city>
        <zip>00100</zip>
        <country>Finland</country>
      </address>
    </facility>
    <contact>
      <last_name>Helka Sahi, MD PhD</last_name>
      <email>helka.sahi@hus.fi</email>
    </contact>
    <investigator>
      <last_name>Helka Sahi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dermatology Dept, Hospital University of Tours</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Mahtab SAMIMI, MD-PhD</last_name>
      <email>mahtab.samimi@univ-tours.fr</email>
    </contact>
    <investigator>
      <last_name>Mahtab SAMIMI, MD-PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Translational Skin Cancer Research</name>
      <address>
        <city>Essen</city>
        <zip>45141</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Jurgen Becker, MD PhD</last_name>
      <email>j.becker@dkfz-heidelberg.de</email>
    </contact>
    <investigator>
      <last_name>Jurgen Becker</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Tumour Institute &quot;Fondazione G. Pascale&quot; Unit of Melanoma - Cancer Immunotherapy and Innovative therapy</name>
      <address>
        <city>Naples</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Paolo Ascierto, MD</last_name>
      <email>paolo.ascierto@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Paolo Ascierto</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Academic Hospital of Maastricht</name>
      <address>
        <city>Maastricht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <contact>
      <last_name>Nicole KELLENERS-SMITH, MD PhD</last_name>
      <email>n.kelleners.smeets@mumc.nl</email>
    </contact>
    <investigator>
      <last_name>Nicole KELLENERS-SMITH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Dermatology, Carol Davila University of Medicine and Pharmacy</name>
      <address>
        <city>Bucharest</city>
        <zip>050474</zip>
        <country>Romania</country>
      </address>
    </facility>
    <contact>
      <last_name>Ana Maria Forsea, MD PhD</last_name>
      <email>aforsea@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Ana Maria Forsea</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Skin Cancer and Surgery Center, Sahlgrenska University Hospital</name>
      <address>
        <city>Gothenburg</city>
        <country>Sweden</country>
      </address>
    </facility>
    <contact>
      <last_name>John Paoli, MD PhD</last_name>
      <email>john.paoli@vgregion.se</email>
    </contact>
    <investigator>
      <last_name>John Paoli</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Dermatology, BaÅŸkent University Faculty of Medicine</name>
      <address>
        <city>Ankara</city>
        <country>Turkey</country>
      </address>
    </facility>
    <contact>
      <last_name>Deniz SECKIN, MD</last_name>
      <email>denizseckin50@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Deniz SECKIN</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth Hospital</name>
      <address>
        <city>Birmingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <contact>
      <last_name>Agustin Martin-Clavijo, MD</last_name>
      <email>agustin.martin-clavijo@uhb.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Agustin Martin-Clavijo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Romania</country>
    <country>Sweden</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>Fan K, Ritter C, Nghiem P, Blom A, Verhaegen ME, Dlugosz A, Ã˜dum N, Woetmann A, Tothill RW, Hicks RJ, Sand M, Schrama D, Schadendorf D, Ugurel S, Becker JC. Circulating Cell-Free miR-375 as Surrogate Marker of Tumor Burden in Merkel Cell Carcinoma. Clin Cancer Res. 2018 Dec 1;24(23):5873-5882. doi: 10.1158/1078-0432.CCR-18-1184. Epub 2018 Jul 30.</citation>
    <PMID>30061360</PMID>
  </reference>
  <reference>
    <citation>Kervarrec T, Tallet A, Miquelestorena-Standley E, Houben R, Schrama D, Gambichler T, Berthon P, Le Corre Y, Hainaut-Wierzbicka E, Aubin F, Bens G, Tabareau-Delalande F, Beneton N, Fromont G, Arbion F, Leteurtre E, TouzÃ© A, Samimi M, GuyÃ©tant S. Diagnostic accuracy of a panel of immunohistochemical and molecular markers to distinguish Merkel cell carcinoma from other neuroendocrine carcinomas. Mod Pathol. 2019 Apr;32(4):499-510. doi: 10.1038/s41379-018-0155-y. Epub 2018 Oct 22.</citation>
    <PMID>30349028</PMID>
  </reference>
  <reference>
    <citation>Paulson KG, Lewis CW, Redman MW, Simonson WT, Lisberg A, Ritter D, Morishima C, Hutchinson K, Mudgistratova L, Blom A, Iyer J, Moshiri AS, Tarabadkar ES, Carter JJ, Bhatia S, Kawasumi M, Galloway DA, Wener MH, Nghiem P. Viral oncoprotein antibodies as a marker for recurrence of Merkel cell carcinoma: A prospective validation study. Cancer. 2017 Apr 15;123(8):1464-1474. doi: 10.1002/cncr.30475. Epub 2016 Dec 7.</citation>
    <PMID>27925665</PMID>
  </reference>
  <reference>
    <citation>Samimi M, Molet L, Fleury M, Laude H, Carlotti A, Gardair C, Baudin M, Gouguet L, Maubec E, Avenel-Audran M, Esteve E, Wierzbicka-Hainaut E, Beneton N, Aubin F, Rozenberg F, Dupin N, Avril MF, Lorette G, Guyetant S, Coursaget P, TouzÃ© A. Prognostic value of antibodies to Merkel cell polyomavirus T antigens and VP1 protein in patients with Merkel cell carcinoma. Br J Dermatol. 2016 Apr;174(4):813-22. doi: 10.1111/bjd.14313. Epub 2016 Feb 3.</citation>
    <PMID>26600395</PMID>
  </reference>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>January 8, 2021</study_first_submitted>
  <study_first_submitted_qc>January 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 12, 2021</study_first_posted>
  <last_update_submitted>May 17, 2021</last_update_submitted>
  <last_update_submitted_qc>May 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>biomarker</keyword>
  <keyword>monitoring</keyword>
  <keyword>prognosis</keyword>
  <keyword>merkel cell polyomavirus</keyword>
  <keyword>miR375</keyword>
  <keyword>T-antigen antibodies</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Merkel Cell</mesh_term>
    <mesh_term>Carcinoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

